MiNT Protein: A New Target to Treat Cancer, Diabetes and Other Diseases?

News   Dec 19, 2017 | Original story from Rice University

 
MiNT Protein: A New Target to Treat Cancer, Diabetes and Other Diseases?

An illustration outlines the NEET cycle in cells by which iron-sulfur clusters are delivered by MiNT, mitoNEET (mNT) and NAF-1 proteins in the cytosol or the mitochondria (bottom) to an array of cellular metabolic processes, including the synthesis of ATP. Credit: Illustration by Patricia Jennings/University of California at San Diego

 
 
 

RELATED ARTICLES

Rapamycin Lotion Reduces Facial Tumors Caused by Tuberous Sclerosis

News

Addressing a critical issue for people with a genetic disorder called tuberous sclerosis complex (TSC), doctors reported that a skin cream containing rapamycin significantly reduced the disfiguring facial tumors affecting more than 90 percent of people with the condition.

READ MORE

Calidi Biotherapeutics, Inc. Announces its Corporate Vision in Groundbreaking Cancer Drug Development

News

Calidi Biotherapeutics, Inc., formerly StemImmune, Inc., a clinical‐stage biotherapeutics company at the forefront of oncolytic virus-based immunotherapies for cancer, announced a focused effort to advance its oncolytic virus drug development.

READ MORE

Bicycle Therapeutics Expands Strategic Partnership with AstraZeneca

News

New programs added in respiratory and cardio-metabolic diseases.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Cancer Research Informatics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE
 

We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy